Protocol Ledger

NCT03599284 · Phase II · COMPLETED

The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

Interventional Phase II clinical trial protocol NCT03599284 sponsored by Jiangsu vcare pharmaceutical technology co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-30 Enrollment: 279 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03599284
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)279 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03599284
Protocol FieldVerified Registry Value
NCT IdentifierNCT03599284
Consolidated Lead SponsorJiangsu vcare pharmaceutical technology co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment279 participants (ACTUAL)
Registered Start Date2018-08-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03599284
Hospital Research SiteLocationSite Profile
Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
Jiangxi Provincial People's HospitalNanchang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI